Jorie Kraus's recovery from a chromosome 10 deletion syndrome via Klonopin, identified through Mayo Clinic's use of the NIH-funded Biomedical Data Translator, offers compelling real-world evidence of AI-driven drug repurposing in neonates. Yet this remains a single-patient case report (observational, n=1) without randomization or controls, limiting causal claims compared to RCTs. The Translator integrates disparate biomedical datasets into a knowledge graph, enabling inferences across literature that clinicians miss, as noted by physician Whitney Thompson. Beyond STAT's coverage, this connects to broader patterns in precision medicine: similar AI tools have accelerated treatments in other ultra-rare conditions, such as a 2023 observational study (n=12) in Genetics in Medicine on graph-based repurposing for developmental encephalopathies, though that work lacked conflicts disclosures and relied on small convenience samples. The original report underplays implementation barriers like uneven genomic sequencing access and confirmatory lab validation delays, while overlooking equity issues in scaling across diverse geographies. A related 2022 review in Nature Reviews Drug Discovery (synthesizing 47 studies, mostly preclinical) highlights AI's strength in rare-disease repurposing but cautions on reproducibility without prospective trials. Jorie's case proves rapid inference is feasible, yet true scalability hinges on embedding such systems in routine care with ongoing peer-reviewed outcome tracking rather than isolated successes.